Abstract
BackgroundAlternative splicing (AS) is one of the critical post-transcriptional regulatory mechanisms of various cancers and also plays a crucial role in the development of cancers, including endometrial cancer (EC).MethodsThe splicing data and gene expression profiles of EC were obtained from The Cancer Genome Atlas. The corresponding clinical data were extracted from TCGA-CDR. With univariate Cox regression analysis, least absolute shrinkage and selection operator model, and multivariate Cox regression analysis, the survival-related AS events were selected. Functional enrichment analysis was also performed to investigate the functions of these AS events. Splicing factors and AS regulation network were constructed to understand the correlation among these AS events.ResultA total of 1826 AS events were identified as survival-related events. Functional enrichment analysis showed that these AS events were associated with several immune system-related processes. Then, the prognostic signatures were developed based on these survival-related events and acted as an independent prognostic factor for EC. Splicing factors and AS regulation network were also constructed to understand the regulatory mechanisms of AS events in EC.ConclusionThis study systematically analyzed the role of AS events in EC and developed the prognostic model for EC.
Highlights
IntroductionEndometrial cancer (EC) is the most common gynecologic malignancy and the fourth most common cancer (about 4.8% of all cancers) in women (Ferlay et al, 2015)
Endometrial cancer (EC) is the most common gynecologic malignancy and the fourth most common cancer in women (Ferlay et al, 2015)
Selection of Survival Associated With Alternative splicing (AS) Events
Summary
Endometrial cancer (EC) is the most common gynecologic malignancy and the fourth most common cancer (about 4.8% of all cancers) in women (Ferlay et al, 2015). EC is generally divided into two subtypes, estrogen-dependent subtype (type I), and estrogen-independent subtype (type II). Type I EC, commonly referred to as the endometrioid type, comprises about 80% of all EC. Most of the Prognostic Splicing of Endometrial Cancer cases of EC are diagnosed in the early stage with relatively good prognosis, there are still over 20% patients who die from the disease due to distant metastasis and recurrence, which often lead to poor response to conventional therapy. It is essential to screen for biomarkers to predict metastasis and recurrence of EC and monitor the prognosis of EC patients effectively. Alternative splicing (AS) is one of the critical post-transcriptional regulatory mechanisms of various cancers and plays a crucial role in the development of cancers, including endometrial cancer (EC)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
